First‐in‐Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers

AG10 is a novel, potent, and selective oral transthyretin (TTR) stabilizer being developed to treat TTR amyloidosis (ATTR). This randomized, double‐blind, placebo‐controlled study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics (ex vivo stabilization) of orally administered AG...

Descripción completa

Detalles Bibliográficos
Autores principales: Fox, Jonathan C., Hellawell, Jennifer L., Rao, Satish, O'Reilly, Terry, Lumpkin, Rick, Jernelius, Jesper, Gretler, Daniel, Sinha, Uma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003869/
https://www.ncbi.nlm.nih.gov/pubmed/31172685
http://dx.doi.org/10.1002/cpdd.700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003869/
https://www.ncbi.nlm.nih.gov/pubmed/31172685
http://dx.doi.org/10.1002/cpdd.700

Ejemplares similares